MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

FVC

  • Home
  • FVC
Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
Posted inClinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

Posted by By MedXY 09/17/2025
The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.
Read More
  • Carotid Artery Stenting Emerges as a Proven Adjunct to Intensive Medical Therapy in Stroke Prevention: Insights from CREST-2
  • Korsakoff Syndrome: Clinical Profiles, Brain Imaging Insights, and Mortality Risks in a Large Cohort
  • IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial
  • Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled Trials
  • Social Inequalities in Gestational Diabetes: Insights from a Nationwide Swedish Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top